Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic comparison of midazolam, propofol, and etomidate for induction in hypertensive patients with ischemic heart disease undergoing open heart surgery
IRCT20120215009014N458Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis and hypertension (HTN) comparing Midazolam induction, Propofol induction and Etomidate induction (3 arms). Primary endpoints: Systolic blood pressure, Diastolic blood pressure and 1 more. Started Feb 2023; status: completed.
02
Drugs
midazolampropofoletomidate
03
Conditions
coronary arteriosclerosishypertension (HTN)
Beyond the preview
Go deeper on IRCT20120215009014N458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N458.